First-in-human phase 1/2 study of the first-inclass sumo-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: Phase 1 results

Authors
Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2021
This article has no abstract
Epistemonikos ID: f938be41f14d44545a800c7a20677556f2ce3f2b
First added on: Feb 13, 2025